{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T11:46:01Z","timestamp":1791459961287,"version":"4.3.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijid.2026.108580","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T16:28:00Z","timestamp":1774110480000},"page":"108580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of long-acting lenacapavir for HIV treatment and prevention: A systematic review of randomized trials"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5251-3323","authenticated-orcid":false,"given":"Blessed Takunda","family":"Mukuhlani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6634-4007","authenticated-orcid":false,"given":"Rufin Kouassi","family":"ASSAR\u00c9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijid.2026.108580_bib0001","first-page":"6","article-title":"The global impact of HIV: a comprehensive review","volume":"4","author":"Khatib","year":"2024","journal-title":"Int J Adv Pharm Sci Res"},{"key":"10.1016\/j.ijid.2026.108580_bib0002","series-title":"Oxford textbook of medicine","first-page":"902","article-title":"Hiv\/Aids","author":"Fidler","year":"2020"},{"issue":"14","key":"10.1016\/j.ijid.2026.108580_bib0003","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1097\/QAD.0000000000001192","article-title":"Population health and individualized care in the global AIDS response: synergy or conflict?","volume":"30","author":"El-Sadr","year":"2016","journal-title":"AIDS"},{"issue":"3","key":"10.1016\/j.ijid.2026.108580_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.59298\/ROJPHM\/2024\/431600","article-title":"Epidemiological trends of HIV\/AIDS in Sub-Saharan Africa: a 2024 perspective","volume":"4","author":"Anitah","year":"2024","journal-title":"Res Output J Public Health Med"},{"issue":"2","key":"10.1016\/j.ijid.2026.108580_bib0005","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4067\/s0716-10182024000200248","article-title":"Situaci\u00f3n epidemiol\u00f3gica de VIH a nivel global y nacional: Puesta al d\u00eda","volume":"41","author":"Blamey","year":"2024","journal-title":"Rev Chil Infectol"},{"issue":"3","key":"10.1016\/j.ijid.2026.108580_bib0006","first-page":"1","article-title":"The impact of Global programs such as PEPFAR, UNAIDS, and the Global Fund on Combating HIV\/AIDS in East Africa","volume":"11","author":"Mwaura","year":"2024","journal-title":"IAA J Sci Res"},{"key":"10.1016\/j.ijid.2026.108580_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.808318","article-title":"Spatial and temporal trends in HIV\/AIDS burden among worldwide regions from 1990 to 2019: a secondary analysis of the global burden of disease study 2019","volume":"9","author":"He","year":"2022","journal-title":"Front Med"},{"key":"10.1016\/j.ijid.2026.108580_bib0008","series-title":"Comprehensive textbook of AIDS psychiatry","first-page":"19","article-title":"HIV\/AIDS in the fourth decade: origins, epidemiology, clinical manifestations, and treatment","author":"Mugavero","year":"2017"},{"issue":"5","key":"10.1016\/j.ijid.2026.108580_bib0009","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/apc.2006.0086","article-title":"Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1\u2013Infected patients","volume":"21","author":"Campo","year":"2007","journal-title":"AIDS Patient Care STDs"},{"issue":"03","key":"10.1016\/j.ijid.2026.108580_bib0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.31690\/ipplanet.2024.v012i03.013","article-title":"\u201cInnovations in HIV treatment: the role of long-acting antiretrovirals examining the advancements in HIV therapy, particularly long-acting injectable antiretrovirals\u201d","volume":"12","author":"Dubey","year":"2024","journal-title":"Innov Pharm Planet"},{"issue":"2","key":"10.1016\/j.ijid.2026.108580_bib0011","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/COH.0000000000000723","article-title":"Promise, perils and cautious optimism: the next frontier in long-acting modalities for the treatment and prevention of HIV","volume":"17","author":"Philbin","year":"2022","journal-title":"Curr Opin HIV AIDS"},{"issue":"Supplement_4","key":"10.1016\/j.ijid.2026.108580_bib0012","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1093\/cid\/ciac752","article-title":"Barriers to uptake of long-acting antiretroviral products for treatment and prevention of HIV in low- and middle-income countries (LMICs)","volume":"75","author":"Kityo","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.ijid.2026.108580_bib0013","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/sextrans-2020-054648","article-title":"Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries","volume":"97","author":"Akinwunmi","year":"2021","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.ijid.2026.108580_bib0014","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.clinthera.2024.01.001","article-title":"Lenacapavir","volume":"46","author":"Beninger","year":"2024","journal-title":"Clin Ther"},{"issue":"S2","key":"10.1016\/j.ijid.2026.108580_bib0015","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.26126","article-title":"Advancing use of long-acting and extended delivery HIV prevention and treatment regimens","volume":"26","author":"Delany-Moretlwe","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"4","key":"10.1016\/j.ijid.2026.108580_bib0016","first-page":"495","article-title":"Pharmacological outlook of lenacapavir: a novel first-in-class long-acting HIV-1 capsid inhibitor","volume":"31","author":"Di Perri","year":"2023","journal-title":"Infez Med"},{"issue":"1","key":"10.1016\/j.ijid.2026.108580_bib0017","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2023.107009","article-title":"Lenacapavir: a novel injectable HIV-1 capsid inhibitor","volume":"63","author":"Hitchcock","year":"2024","journal-title":"Int J Antimicrob AGENTS"},{"issue":"6","key":"10.1016\/j.ijid.2026.108580_bib0018","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14787210.2023.2203913","article-title":"Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options","volume":"21","author":"Tuan","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijid.2026.108580_bib0019","doi-asserted-by":"crossref","unstructured":"Adu-Ampratwum D, Annamalai AS, Dinh T, Lockwood JR, Bockbrader RH, Haney R, et al. Delineating structural functionalities of lenacapavir amenable to modifications for targeting emerging drug-resistant HIV-1 capsid variants. 2025 [accessed October 12 2025]. Available from: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/685962b31a8f9bdab5206132","DOI":"10.26434\/chemrxiv-2025-2k94j"},{"issue":"5","key":"10.1016\/j.ijid.2026.108580_bib0020","article-title":"Lenacapavir: advancing HIV control requires resistance vigilance and equitable access","volume":"1","author":"Amin","year":"2025","journal-title":"INNOVAPATH"},{"key":"10.1016\/j.ijid.2026.108580_bib0021","doi-asserted-by":"crossref","unstructured":"Paik J. Lenacapavir: first approval. 2022;82(14):1499\u2013504.","DOI":"10.1007\/s40265-022-01786-0"},{"issue":"3","key":"10.1016\/j.ijid.2026.108580_bib0022","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/jac\/dkae480","article-title":"Safety and efficacy of long-acting cabotegravir\/rilpivirine versus standard oral antiretroviral therapy: a systematic review and meta-analysis","volume":"80","author":"Manalu","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ijid.2026.108580_bib0023","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/cid\/ciae631","article-title":"Virologic failure and emergent integrase strand transfer inhibitor drug resistance with long-acting cabotegravir for HIV treatment: a meta-analysis","volume":"81","author":"Perez Navarro","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2026.108580_bib0024","doi-asserted-by":"crossref","DOI":"10.2196\/46767","article-title":"Safety and efficacy of long-acting injectable agents for HIV-1: systematic review and meta-analysis","volume":"9","author":"Wang","year":"2023","journal-title":"JMIR Public Health Surveill"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226002158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971226002158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T20:24:38Z","timestamp":1778099078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971226002158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S1201971226002158"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108580","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of long-acting lenacapavir for HIV treatment and prevention: A systematic review of randomized trials","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108580"}}